American biotechnology company Moderna July 27 began the third and final phase of testing potential vaccines against coronavirus infection. This writes the Associated Press.
It is expected that the research will take part about 30 thousand volunteers. They should split into groups: some will receive the real drug, the control group a placebo. After two injections all participants return to daily activities and remain under supervision of scientists.
The first group of subjects were vaccinated in Savannah (GA).
As noted by the “Voice of America”, this is the first tests that are carried out in the framework of the government program “Operation Superluminal speed”, aimed at accelerating the development, production and distribution of medicines and vaccines from COVID-19.
In this programme, Moderna received from the government of the United States, about a billion dollars and chose developed a vaccine to conduct a large-scale human trials.
In mid-July, the company announced the successful completion of the second phase of clinical trials. It was attended by 45 people, aged 18 to 55 years.
“The vaccine mRNA-1273 provoked the immune responses of all participants. In addition, there were no problems limiting testing”, – stated in the annotations to the study published in the journal the New England Journal of Medicine. At the same time, half of the participants the vaccine caused side effects in mild or moderate degree, such as weakness, chills, headache, and pain at the injection site.
Special medications from COVID-19 does not exist now in this disease is only symptomatic treatment. The world health organization notedthat a number of medicines can contribute to improved well-being and relief of symptoms COVID-19, but there is no evidence that any drug to prevent or treat the disease.
The head of the European Agency of medicines Marco Kavaleri previously reported that a vaccine for the coronavirus in the best case will be ready next year. May 15, U.S. President Donald trump suggested that the vaccine for coronavirus can be created and tested until the end of 2020.
According to who, currently about 120 trials of a vaccine against coronavirus SARS-COV-2 / COVID-19 worldwide.